Liminal BioSciences Stock Is Trading Higher On Sale Of Priority Review Voucher For $105M

  • Liminal BioSciences Inc's LMNL subsidiary Prometic Biotherapeutics Inc has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $105M.
  • The FDA granted the PRV with the approval of Ryplazim (plasminogen, human-tvmh) for plasminogen deficiency type 1 (hypoplasminogenemia).
  • Hypoplasminogenemia is characterized by a lack of a plasminogen protein, causing the development of growths (lesions) that can impair normal tissue and organ function.
  • Liminal Biosciences is entitled to retain an amount equal to 70% of the net sales proceeds of the sale of the PRV. 
  • Jefferies LLC acted as exclusive financial advisor to Liminal BioSciences Inc. on this transaction.
  • Price Action: LMNL shares are up 29% at $3.69 during the market session on the last check Monday.
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareAsset SalesMoversTrading IdeasGeneralBriefsFDA Priority Review